Galapagos Reports New Post-Hoc Analyses from P-III SELECTION Program of Filgotinib to Treat Ulcerative Colitis
Shots:
- The P-III SELECTION trial comprises 2 induction trials & a maintenance trial evaluating filgotinib (200/100 mg) vs PBO in adult patients with active UC
- Induction studies results: improvements in PROs of SF & RB in biologic-naïve & biologic-experienced patients (200mg dose). In induction study A & B (18.8% vs 9.5% & 10.7% vs 4.2%) patients achieved a composite score of RB & SF as early as 9 & 7 day respectively
- In maintenance study- patients demonstrated CS-free remission @58wks.- CS free in 6 & 8mos. (27% & 22% vs 6% & 6%). The safety analysis from all studies showed that the results are consistent with original induction & maintenance trials & was well tolerated
Ref: Globe Newswire | Image: Made in
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com